Researchers at Washington University School of Medicine in St. Louis have developed a potential antibody-based approach to ...

Antibodies made by the immune system can sometimes target human brain cells, producing psychiatric symptoms. Researchers aim ...

Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 ...

Lund University. For most of his career as a researcher, Lars Björck has sought to understand how bacteria manage to evade ...

When reading through medical records, I sometimes encounter stories that have nothing to do with tests or medications. How ...

When I finish explaining a treatment, silence sometimes falls over the examination room. The patient stares at a point on the ...

AstraZeneca will put about $2 billion into Summit after the latter flagged in July that its cash pile was not enough to fund planned operations for a full year.

Treatment options for patients with relapsed/refractory follicular lymphoma have expanded rapidly. CD19-directed CAR T-cell therapies are approved in the third-line setting and beyond, and CD20 x CD3 ...

Red Queen Bio is using artificial intelligence to design antibody drugs for novel pathogens—before future AI systems create ...

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, ...

Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers (TCEs).

The findings in the journal Immunity provide a new target for developing a vaccine against P. vivax, the most wide spread ...